In Europe, Borrelia burgdorferi sensu lato, the etiologic agent of Lyme borreliosis, comprises three species pathogenic for humans (4) . Many antigens of B. burgdorferi sensu lato have been described to be heterogeneous between the three species B. burgdorferi sensu stricto, Borrelia afzelii, and Borrelia garinii. The molecular variability was especially demonstrated for the plasmid-encoded antigens OspA (43, 47) , OspC (19, 41, 48) , and OspD (23) , whereas chromosomally encoded antigens like p83/100 (32) and flagellin (19) are more conserved. Among different strains of B. garinii this antigenic variability of defined antigens is more pronounced, e.g., OspA types 3 to 8 (44) . Several studies have shown differences in immunoblot reactivity patterns depending on the strain, serotype, or species used as the antigen (8, 16, 24, 26, 49, 50) . Proper identification of reactive bands and thus comparison of the reactivities of defined borrelial proteins is difficult in immunoblots with ultrasonicated antigens (conventional immunoblotting). Recently, we showed differences in reactivity among homologous proteins derived from representatives of the three species pathogenic for humans using recombinant proteins for the proper identification of reactive proteins (45) . Such differences were shown for OspA, OspC, p83/100, and truncated flagellin in the immunoblot (45) as well as by other investigators with enzymelinked immunosorbent assay (ELISA) for truncated flagellin (6) and for OspC with conventional immunoblots (24) .
Simpson et al. (38) described a specific and sensitive antigen for the serodiagnosis of Lyme disease in U.S. patients. Several studies (all done with B. burgdorferi sensu stricto antigen) confirmed the high value of P39 as a serodiagnostic antigen (9-11, 16, 22, 27, 35) . Recently, the gene locus for P39 was identified in B. burgdorferi sensu stricto strain Sh-2-82 by Simpson and coworkers (37) . The chromosomally encoded bmpA gene is located in a bmp gene cluster consisting of bmpA to bmpD (31) . The bmpA gene is arranged tandemly with bmpB (37) downstream of the putative monocistronic transcribed bmpD or bmpC (31) . The deduced translation products of all four bmp reading frames are of similar size and contain putative cleavage sites for signal peptidase II, and thus, their locations might be within the borrelial membrane, as shown for BmpA (40) . Only BmpA (P39) of the bmp gene cluster is described as an important immunogenic protein for the serodiagnosis of Lyme borreliosis. So far, no data on the in vivo expression and immunogenicity of bmpB, bmpC, or bmpD are available. The molecular heterogeneity of BmpA (P39) among the three B. burgdorferi sensu lato species pathogenic for humans and its possible effects on the serodiagnosis of Lyme borreliosis in Europe have not been investigated yet.
Thus, we analyzed the molecular and immunological heterogeneities of BmpA proteins among B. burgdorferi sensu lato isolates. We found considerable heterogeneity among BmpA proteins and evaluated the influence of this heterogeneity on serodiagnosis. Seven BmpA-specific monoclonal antibodies (MAbs) were produced with recombinantly expressed BmpA. They were tested for their reactivities with BmpA of B. burgdorferi sensu lato (OspA types 1 to 7). Recombinant BmpA was highly specific but a weak marker for immunoglobulin M (IgM), and the BmpA proteins of B. afzelii and B. garinii were more than twice as sensitive as B. burgdorferi sensu stricto BmpA at detecting IgG antibodies.
(Part of this work was presented at the VII International Congress on Lyme Borreliosis, San Francisco, Calif., 16 to 21 June 1996.)
MATERIALS AND METHODS
Patient sera. Sera from the following groups of patients with Lyme borreliosis (n ϭ 86) and controls (n ϭ 73) were investigated. Sera from unselected, untreated patients (n ϭ 30) with erythema migrans (EM) were obtained by a dermatologist during a former study of therapy for Lyme borreliosis (42) . The median of the time period between the onset of the EM and serum sampling was 2 weeks (range, 2 days to 19 weeks). The neuroborreliosis group (n ϭ 30) included untreated patients with typical signs of acute neuroborreliosis (NB): cerebrospinal fluid (CSF) pleocytosis and specific IgG CSF/serum indexes of Ն2.0. All serum specimens were obtained on the same day as the CSF specimens. The median time of onset of the neurological symptoms before the serum samples were obtained was 4 weeks (range, 2 to 18 weeks). The group with late Lyme borreliosis (n ϭ 26) comprised 16 patients with acrodermatitis chronica atrophicans (ACA) diagnosed by a dermatologist and 10 patients with Lyme arthritis (AT). Possible differential diagnoses had been excluded. Sera from 52 healthy blood donors, sera from 10 patients with syphillis in stage II or III, and 11 serum specimens with rheumatoid factor levels of Ն45 IU/ml served as controls. The actual healthy blood donors had no history of frequent tick bites, erythemas, neurological symptoms, or joint disorders.
Borrelia sp. strains and cultivation. The B. burgdorferi strains used in this study (Table 1) were grown in modified Kelly medium at 33°C for 4 to 5 days as described previously (30) . All strains have been described and classified previously (44, 47, 48) .
PCR, molecular cloning, and sequencing. If not mentioned otherwise, standard techniques of molecular cloning were performed as described elsewhere (2) . Total genomic B. burgdorferi DNA was extracted as described previously (21) . The coding regions of bmpA and bmpB were amplified by PCR in a Perkin-Elmer 9600 thermal cycler under standard conditions (20 pmol of each of the 5Ј and 3Ј primers) by using AmpliTaq DNA polymerase (PE Applied Biosystems, Weiterstadt, Germany). After initial denaturation of chromosomal DNA for 3 min at 96°C, a total of 30 cycles (96°C for 1 min, 42°C for 1 min, 72°C for 2 min) were performed. The 5Ј forward and 3Ј reverse primers for PCR amplification as well as the sequencing primers for bmpA and bmpB are listed in Table 2 . The primers were designed according to the bmpAB sequence published for strain Sh-2-82 (37) (GenBank accession no. L24194) and results obtained from sequence alignments. The primers used for amplification of the overall bmpA gene including the signal sequence were bmpA-A1 and bmpA-B1. For expression cloning of bmpA, leaving out the coding region of the signal peptide but with six additional histidine residues fused to the 3Ј terminus, primer pair bmpA-A3 and bmpA-B2 was used. The resulting PCR amplicon was used to produce an in-frame construct of bmpA lacking its own 3Ј signal sequence but containing the Escherichia coli ompA signal sequence of the secretory pASK40 expression vector (39) . PCR amplification of the 3Ј-truncated bmpA gene was carried out with primer pair bmpA-A3 and bmpA-D. The overall bmpB coding region was amplified by PCR with primers bmpB-A1 and bmpB-B1. For cloning of bmpA and bmpB, PCR fragments were either cloned directly into pCR II (Invitrogen, Leek, The Netherlands) or cut with a restriction enzyme (Boehringer Mannheim GmbH, Mannheim, Germany), purified by agarose gel electrophoresis (FMC NuSieve GTG agarose; Biozym, Hess. Oldendorf, Germany), and eluted (QIAquick Gel Extraction Kit; Qiagen, Hilden, Germany). About 60 fmol of the expression unit was ligated with 6 fmol of an appropriately prepared pUC18 (BamHI, PstI) or pASK40 (KpnI, HindIII) expression vector by standard procedures. Competent E. coli JM83 cells were electroporated (Gene Pulser II; Bio-Rad, Munich, Germany) with a 10% aliquot of the ligation mixture (ethanol precipitated). Transformants were selected after restriction analysis, and subsequent DNA sequencing was performed on an ABI 377 DNA Sequencer (ABI Prism dye terminator cycle sequencing; Perkin-Elmer Applied Biosystems, Weiterstadt, Germany).
Sequence comparison. Sequence comparison was done as described previously (32) .
Expression of rBmpA, purification, and protein characterization. The selected transformants (E. coli JM83) harboring the expression plasmids to produce ANSSSVP[F15-I339]6ϫH-BmpA in pASK40 were 1611 (PKo), 2615 (B31), and 3613 (PBi). Cells were grown, induced with isopropyl-␤-D-thiogalactopyranoside, and harvested as described previously (6) . E. coli cells were lysed (50 mM sodium phosphate buffer [pH 8.0], lysozyme [0.4 g/ml], Benzonase [2.5 U/ml; Merck, Darmstadt, Germany]) for 30 min at room temperature and ultrasonicated, and the suspension was adjusted to contain 500 mM NaCl and 1 mM imidazole and centrifuged at 10,000 ϫ g for 15 min. The supernatant containing soluble recombinant BmpA (rBmpA) was then filtered through a 0.2-m-pore-size filter. For isolation of partial insoluble rBmpA of strains B31 (2615) and PBi (3613), urea was added to the cell lysate to a final concentration of 4 M before ultrasonication. For subsequent metal chelate chromatography, NaCl and imidazole were added so that the final concentrations were 500 mM NaCl, 5 mM imidazole, and 2 M urea in 50 mM sodium phosphate buffer (pH 8.0).
rBmpAs containing C-terminal hexahistidine residues were purified by immobilized metal chelate affinity chromatography (17) . rBmpA was loaded in buffer A (50 mM sodium phosphate [pH 8.0], 500 mM NaCl, 5 mM imidazole). For insoluble rBmpAs of strains PBi and B31, buffer A with 2 M urea was used. Elution was performed with a linear gradient of from 0 to 500 mM imidazole in buffer A on an FPLC system (Pharmacia Biotech, Freiburg, Germany). Detection of rBmpA was performed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and MAbs (see following sections). Fractions containing rBmpA were pooled, dialyzed against 20 mM Tris-OH/HCl (pH 8.0), and subsequently purified by anionexchange chromatography on a MonoQ column with a linear gradient from 0 to 500 mM NaCl. rBmpA was analyzed for impurities by immunoblotting with a broadly reactive polyclonal E. coli antiserum (K69) derived from rabbits. Nterminal sequencing of rBmpA was performed with a gas-phase sequencer (ABI 473A; PE Applied Biosystems) by following the instructions of the manufacturer.
MAbs. MAbs were raised against purified rBmpA of strains PKo and B31 and were identified by ELISA with rBmpA or with conventional immunoblots by using B. burgdorferi whole-cell lysates by methods described previously (32) . Hybridomas were produced by standard techniques (13) . Cloning and determination of the immunoglobulin class and isotype were performed as described previously (46) . An MAb against P39 (MAb H1141) was kindly provided by Tom Schwan (Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, Hamilton, Mont.) and was used at a 1:500 dilution.
SDS-PAGE and Western immunoblots. The protein concentration was determined by the method of Bradford (5) or by measuring the optical density at 280 nm. Preparative discontinuous SDS-PAGE (12.5% polyacrylamide) was carried out by standard procedures (20) with gels that were 17 cm in width and 9 cm in length and that had 0.75-mm spacers. Four preparative SDS-PAGE runs, one for each rBmpA (3.6 g of rBmpA/per gel) and one gel with a mixture of all three rBmpAs (equal amounts of B31, PKo, and PBi rBmpAs; total, 3.6 g) were performed. After SDS-PAGE, zones containing rBmpA were cut out of the gels, and all four gel slices were subjected in parallel to Western blotting on one sheet of a Immobilon-P polyvinylidene difluoride membrane (Millipore, Eschborn, Germany) by the semidry technique described by the manufacturer (2-h blotting time). Membranes were blocked for 1 h at 37°C (50 mM Tris-OH/HCl [pH 7.4], 200 mM NaCl, 0.1% Tween 20, 5% nonfat dried milk) and cut into 68 strips (2.5 mm in width), and successful protein transfer onto the polyvinylidene difluoride membrane was analyzed by staining the two outer strips of each gel by using the colloidal gold enhancement kit (Bio-Rad). The strips were dried and stored for up to 2 weeks at 4°C. The estimated amount of each rBmpA or the rBmpA mixture per immunoblot strip was approximately 30 ng. MAb L39B5 and a positive patient serum sample served as positive controls.
Prior to IgM testing, sera were pretreated with reumathoid factor absorbent (Behringwerke AG, Marburg, Germany). Strips were incubated with sera at room temperature overnight with 1:200 and 1:100 dilutions (in 10 mM Tris-OH/ HCl [pH 7.4], 150 mM NaCl, 0.2% Tween 20, 1% nonfat dried milk) for IgG and IgM immunoprints, respectively, washed, and incubated for 2 h with horseradish peroxidase-conjugated anti-human IgG and IgM antibodies (Dakopatts, Copenhagen, Denmark) at a dilution of 1:1,000 for IgG detection and a dilution of 1:500 for IgM detection. Color was developed by adding diaminobenzidine and H 2 O 2 . All sera were randomized before testing. Incubation and evaluation were performed in a blinded manner, and semiquantitative evaluation of the strips was independently done by two persons.
To verify the diagnostic value of rBmpA, results from this study were compared to the results obtained with natural BmpA (nBmpA) (derived from whole borrelial cell lysates and conventional immunoblotting) in a former standardization study (16) with the same 86 serum specimens from patients with Lyme borreliosis and Borrelia strains but not the same B. burgdorferi strains (strain PKa2 was used instead of B31).
Nucleotide sequence accession numbers. The newly identified bmpA and bmpB sequences of B. burgdorferi sensu lato strains were submitted to the EBI database and have the accession numbers presented in Table 1 .
RESULTS
BmpA and BmpB sequence heterogeneity. The coding regions (positions 43 to 1020) of bmpA were amplified from the 12 B. burgdorferi sensu lato strains listed in Table 1 . Only bmpA of B. garinii PBr, TN, and PKi failed to give a full-length PCR product and were amplified as shorter products lacking approximately 180 to 230 bp at the 3Ј terminus.
The deduced amino acid sequences showed a high degree of identity (86.4 to 99.7%) if single sequences were compared to the previously described BmpA of B. burgdorferi sensu stricto strain Sh-2-82. Alignment studies at the amino acid level (amino acid positions 15 to 257; numbering for strain Sh-2-82) showed highly conserved BmpA within B. burgdorferi sensu stricto (98.7 to 99.7% identity) and B. afzelii strains (98.5 to 99.4% identity), whereas B. garinii BmpA appeared to be more heterogeneous (91.4 to 97.5% identity). The interspecies identities between the three B. burgdorferi species pathogenic for humans ranged from 86.4 to 91.6%. Cluster analysis of the BmpA sequences (amino acid positions 15 to 257; numbering for strain Sh-2-82) showed three main clusters representing the three species and a higher variability within B. garinii BmpA compared to that within the BmpA proteins of B. afzelii and B. garinii (Fig. 1) . The average identity of the BmpA sequences compared to that of the BmpB sequence is 57.7%. The theoretically determined isoelectric points of BmpAs (varying from pI 4.96 to pI 5.98) were confirmed by isoelectric focusing with the rBmpAs of strains B31, PKo, and PBi (data not shown).
The three amplified bmpB sequences of strains B31, PKo, and PBi were compared to the previously published sequence of strain Sh-2-82. The identities of the deduced amino acid sequences ranged from 97.9% between the two B. burgdorferi sensu stricto strains (B31 and Sh-2-82) to 83.8 and 85.6% compared to the BmpB sequence of B. garinii PBi and the BmpB sequence of B. afzelii PKo, respectively. N-terminal sequence of rBmpA. For internal quality assurance and to test the integrity of the secreted and purified rBmpA, the material was subjected to N-terminal sequencing. As expected, the rBmpA of strain B31 revealed a homogeneous N terminus harboring the seven additional amino acid residues derived from the OmpA signal sequence linker peptide of pASK40 (ANSSSVP-[F15-I339]6ϫH-BmpA). Recombinant BmpA of strain PKo showed the expected N terminus (about 40%) as well as an N-terminal prolonged variant (60%) with an additional six amino acid residues (underlined), ATV AQAANSSSVP-[F15-I339]6ϫH-BmpA. rBmpA of strain PBi showed N-terminal truncated forms missing 4 (approximately 50%) or 11 amino acid residues resulting in SVP-[F15-I339] 6ϫH-BmpA or [S19-I339]6ϫH-BmpA of strain PBi.
Isolation, characterization, and reactivities of MAbs. After screening by ELISA with rBmpA as the antigen as well as by conventional immunoblotting with B. burgdorferi total cell ly-sates (data not shown), seven different BmpA-specific MAbs (MAbs L39B1, L39B2, L39B3, L39B5, L39B7, L39B8, and L39B10) could be identified. All MAbs belong to the IgG1 subclass. One MAb (MAb L39B8) was reactive with B. afzelii (strains PKo and PGau; OspA type 2) and B. garinii (strains PBr, PBi, W12, TN, and T25; OspA types 3 to 7, respectively) but not with B. burgdorferi sensu stricto (strains PKa2 and B31; OspA type 1) by using conventional immunoblots. All other MAbs were reactive with all three species of B. burgdorferi sensu lato. None of the antibodies was reactive with whole-cell lysates of relapsing fever borreliae (Borrelia recurrentis, Borrelia duttonii, Borrelia parkeri, Borrelia hermsii, and Borrelia turicatae) or Treponema pallidum, Treponema phagedenis, Treponema denticola, Leptospira grippotyphosa, Listeria monocytogenes, Legionella micdadei, or Salmonella typhimurium (data not shown).
All MAbs were also tested for their reactivities with rBmpA of strains B31, PKo, and PBi. MAb L39B8 recognized only the rBmpA proteins of B. garinii PBi and B. afzelii PKo but not the rBmpA of B. burgdorferi sensu stricto strain B31 (Fig. 2, lane  D) . All other MAbs were reactive with recombinant BmpAs from all three species (Fig. 2 , lane C; MAb L39B5). A BmpAspecific monoclonal antibody (MAb H1141) recommended by the Centers for Disease Control and Prevention for the calibration of immunoblots in the United States showed weak reactivity with rBmpA of B. afzelii PKo, no reaction to rBmpA of B. garinii PBi, but a clear reaction with rBmpA of B. burgdorferi sensu stricto strain B31 (Fig. 2, lane E) . The same results were obtained with MAb H1141, but by using B. burgdorferi sensu lato whole-cell lysates in conventional immunoblots (data not shown).
Serological testing of rBmpA. A panel of serum specimens from 86 patients and 73 controls was tested for the strainspecific reactivities of the sera with the rBmpAs of strains PKo, B31, and PBi in immunoblots and with a mixture of the three rBmpAs.
To determine the cutoff criteria for positive results, control serum specimens from 73 healthy control persons were examined. A five-grade criterion evaluation (strongly positive, positive, weakly positive but definitely positive, detectable "shading," and no reaction) was performed. Only 1 of the 73 control serum samples reacted weakly positive by IgG testing with rBmpA of strain B31. None of the other serum specimens were reactive (Table 3) , thus giving specificities of 100% for rBmpA of PKo, PBi, or the rBmpA mixture and 98.6% for rBmpA of (Table 3) . IgM antibodies were detected in only 1.1 to 8.1% of the Lyme borreliosis patients. In contrast, IgG sensitivities for the three rBmpAs and the rBmpA mixture were significantly higher (Table 4) . Recombinant BmpA of PKo or PBi and the rBmpA mixture reacted more than twice as often (34.9 to 36.0% overall sensitivity) in the IgG immunoblot than rBmpA of B31 (13.9%) alone. IgG antibodies were detected by the rBmpAs of strains PKo and PBi in 65 to 69% of the sera from patients with stage III of the disease (AT plus ACA), 33 to 40% of the sera from patients with stage II (NB), and only 6.6% of the sera from patients with the early (EM) stage (Table 4 ). In contrast, rBmpA of B. burgdorferi sensu stricto strain B31 was recognized by none of the sera from patients with stage I, only 10% of the sera from patients with stage II, and 34.6% of the sera from patients with stage III, resulting in this low overall sensitivity. The rBmpA mixture used in this study showed IgG sensitivities similar to that of rBmpA of strain PKo or strain PBi alone (Table 4) . Results for a selection of various IgG-positive patient sera are presented in Fig. 2 , lanes F to L.
DISCUSSION
Many studies have indicated that strain heterogeneity has a considerable influence on the serodiagnosis of Lyme borreliosis, especially in Europe (16, 24, 45, 50) . Therefore, we investigated by molecular and immunological methods BmpA (P39) from various B. burgdorferi sensu lato strains and evaluated the serological reactivity of the respective recombinantly expressed antigens with sera from Lyme borreliosis patients.
We found considerable heterogeneity among BmpAs derived from strains belonging to different species of B. burgdorferi sensu lato. This was also true for B. garinii strains, whereas BmpA was highly conserved among B. afzelii and B. burgdorferi sensu stricto strains. The topology of the BmpA cluster analysis is similar to that of the chromosomally encoded p83/100 (32) or to that of the plasmid-encoded OspA (43) and reflects heterogeneity among the three species as well as the intraspecies heterogeneity found solely among different strains of B. garinii.
Since BmpA is heterogeneous and variable regions are evenly distributed (only the region between amino acid positions 164 and 184 is highly conserved), this heterogeneity might influence serodiagnosis. Therefore, BmpAs from three different B. burgdorferi species were expressed recombinantly in E. coli. The expression of recombinant protein in a soluble form was most effective when an E. coli secretory system with the E. coli OmpA signal sequence instead of the BmpA signal sequence was used. Variations within the N terminus (linker peptide) of the expression products might be explained by an inaccurate endoproteolytic cleavage of the E. coli signal peptidase during secretion. Unfortunately, no data on the expression and purification procedure of recombinant P39 used by other investigators are available in the literature (11, 27, 34) . Thus, the presence of the BmpA signal sequence within the recombinant protein and its possible influence on the sensitivity of serodiagnosis remain unclear.
The BmpA molecule has epitopes conserved among the three species, as shown by MAbs L39B1, L39B2, L39B3, L39B5, L39B7, and L39B10. These MAbs were specific for BmpA of B. burgdorferi sensu lato, did not show any reactivity with relapsing fever borreliae or other treponemes, and thus can possibly be used for the specific detection of B. burgdorferi sensu lato antigens. Whereas attempts to develop a borrelial vaccine solely with outer surface proteins appear to be successful (12, 29, 33) , the importance of P39 for a protective immune response is still controversial (15, 18, 36) . The potential bactericidal capability of the MAbs presented here must be evaluated in future experiments.
MAb H1141 recommended by the Centers for Disease Control and Prevention (7) for the calibration of immunoblots showed a preferential reactivity with BmpA of B. burgdorferi sensu stricto, weak reactivity with B. afzelii, but no reactivity with B. garinii, irrespective of the nature of BmpA (whole-cell lysate in conventional or single rBmpA in recombinant immunoblots). On the other hand, MAb L39B8 reacted with B. afzelii and B. garinii but failed to react with B. burgdorferi sensu stricto. Since in Europe all three species, B. burgdorferi sensu stricto, B. afzelii, and B. garinii, have been isolated from patients (3, 47) , we recommend the use of BmpA-specific MAbs recognizing conserved epitopes for the calibration of immunoblots.
The serological specificity of rBmpA is in good accordance with the results of other studies. Only a low specificity was described by Dressler et al. (9) , who used conventional immunoblotting. Others reported specificities that ranged from 94 to 100% (1, 11, 16, 22, 25, 27, 34) . Data for sensitivities of the P39 IgM test are controversial, depending on the assay system used, and may also be influenced by the manifestation of the disease. In our hands rBmpA was not a useful antigen for IgM antibody detection. Results from laboratories in the United States varied considerably, with the assays having from low (1, 9) to high (10, 22) sensitivities. Those studies used conventional blots with B. burgdorferi sensu stricto as the antigen, and it is not clear whether the band at 39 kDa identified in those blots truly represents BmpA. Very recent immunoprint data presented by Padula et al. (28) are in agreement with a general low IgM reactivity of this protein.
The diagnostic sensitivity of the rBmpA IgG test in this study is in accordance with most data from other investigators (1, 9-11, 22, 34) . rBmpA and nBmpA in the conventional blot appear to be equally sensitive. Only Oksi and coworkers (27) found a very low sensitivity (14.6% for a B. burgdorferi sensu stricto-derived P39 ELISA), even though the sera investigated were defined to be from patients with late-stage disease. Since these patients were from Northern Europe (Finland), it appears reasonable that the lack of sensitivity is at least partially caused by the use of recombinant B. burgdorferi sensu stricto P39 as a single antigen. Our results indicate that rBmpAs from strains PKo and PBi are considerably more sensitive than rBmpA of B. burgdorferi sensu stricto alone for the serodiagnosis of Lyme borreliosis in European patients. Thus, a significant increase in sensitivity can be achieved by using rBmpA of B. afzelii and B. garinii, in addition to or instead of B. burgdorferi sensu stricto BmpA. None of the sera tested in this study showed an exclusive reaction with rBmpA of B. burgdorferi sensu stricto but lacked reactivity with rBmpA of the other two species. However, it cannot be excluded that infection with B. burgdorferi sensu stricto may lead to antibodies solely reactive with B. burgdorferi sensu stricto BmpA.
In our hands recombinant BmpA is as sensitive as nBmpA for the detection of IgG antibodies in patients with stage I and stage II manifestations. There are different explanations for a higher sensitivity of the blot with the whole-cell lysate late in the course of the disease. Late in the course of the disease a very broad panel of proteins is recognized by the sera. Thus, especially the use of conventional blots does not exclude the recognition of other overlying borrelial proteins with similar apparent molecular masses by SDS-PAGE. Recently, a flagellum-associated protein, FlaA, with an estimated size of approximately 38 kDa has been described (14) . In addition, not all members of the bmp gene cluster have been examined for transcription and translation in vivo (31) , and it has not been examined whether they are immunogenic. Since bmpB, bmpC, and bmpD are similar in size, their putative translation products might appear as one protein band in conventional immunoblots if they are expressed by the borreliae and recognized by patient sera. A reason for the lower sensitivity of rBmpA compared to that of nBmpA might also be the expression of rBmpA without its own signal sequence.
For the serodiagnosis of Lyme borreliosis in Europe, we recommend the use of rBmpA derived from all three species and the use of BmpA-specific MAbs recognizing conserved epitopes for the standardization of immunoblots.
